IDiyas

For the Inventor, By the Inventor

Staten Island, NY, United States of America

Fa-Xiang Ding

USPTO Granted Patents = 31 

 

Average Co-Inventor Count = 7.3

ph-index = 4

Forward Citations = 65(Granted Patents)


Location History:

  • Kenilworth, NJ (US) (2018)
  • Staten Island, NJ (US) (2022)
  • Staten Island, NY (US) (2009 - 2023)

Company Filing History:

goldMedal29 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal2 out of 207 
 
Aventis Pharmaceuticals Inc.
 patents

Years Active: 2009-2025

Loading Chart...
Loading Chart...
31 patents (USPTO):
1. 12448384 - Diacylglyceride O-acyltransferase 2 inhibitors (2025-10-21),
2. 12209145 - PCSK9 antagonist compounds (2025-01-28),
3. 12178842 - PCSK9 antagonist compounds (2024-12-31),
4. 11738010 - Oxazolidinones as TarO inhibitors (2023-08-29),
5. 11484565 - PCSK9 antagonist compounds (2022-11-01),
6. 11427616 - PCSK9 antagonist compounds (2022-08-30),
7. 11306125 - PCSK9 antagonists bicyclo-compounds (2022-04-19),
8. 11230543 - Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections (2022-01-25),
9. 11141410 - Oxazolidinones as taro inhibitors (2021-10-12),
10. 10947222 - Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 (2021-03-16),
11. 10407421 - Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections (2019-09-10),
12. 10208064 - Inhibitors of the renal outer medullary potassium channel (2019-02-19),
13. 10000484 - Inhibitors of the renal outer medullary potassim channel (2018-06-19),
14. 9926317 - Inhibitors of the renal outer medullary potassium channel (2018-03-27),
15. 9862720 - Inhibitors of the renal outer medullary potassium channel (2018-01-09),

Title: The Inventor Shaping the Future of Pharmaceutical Innovations: Fa-Xiang Ding

Introduction: Fa-Xiang Ding, a prolific inventor based in Staten Island, NY, is making significant strides in the field of pharmaceutical research and development. With an impressive portfolio of 28 patents to his name, Ding is revolutionizing the healthcare industry with his groundbreaking inventions.

Latest Patents:

1. Oxazolidinones as TarO inhibitors: Ding's latest patent introduces novel compounds that inhibit TarO, offering potential in the prevention and treatment of bacterial infections, including MRSA and MRSE.

2. PCSK9 antagonist compounds: Another notable invention by Ding includes compounds that antagonize PCSK9, aiding in the treatment of cardiovascular diseases like atherosclerosis and hypercholesterolemia.

Career Highlights: Ding has contributed his expertise to renowned companies such as Merck Sharp & Dohme Corporation and Aventis Pharmaceuticals Inc., where he played a pivotal role in driving innovation and pushing the boundaries of pharmaceutical research.

Collaborations: Throughout his career, Ding has collaborated with esteemed professionals in the field, including Jinlong Jiang and Shuzhi Dong. Together, they have fostered a culture of innovation and excellence, leading to groundbreaking discoveries in the pharmaceutical industry.

Conclusion: Fa-Xiang Ding's relentless pursuit of innovation and his dedication to advancing healthcare technologies have solidified his reputation as a visionary inventor. His patents and collaborations underscore his commitment to pushing the boundaries of scientific discovery, making him a key figure in the world of pharmaceutical innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…